New drug for alopecia areata
Concert Pharma recently released the results of its phase II clinical trial evaluating the dose range of the experimental deuterated CTP-543 for patients with moderate to severe alopecia areata, an […]
Read More →JAK1 inhibitor Rinvoq (upadacitinib) approved by the FDA in the United States
Upadacitinib tartrate, a small-molecule selective inhibitor of JAK1, was recently approved in the U.S. as a treatment for adults with moderately to severely active rheumatoid arthritis (RA) and an inadequate response […]
Read More →Research and Development of Janus Kinase (JAK) Inhibitors
Introduction of JAK-STAT signaling Pathway The JAK-STAT signaling pathway is a signal transduction pathway stimulated by cytokines, which is involved in many important biological processes such as cell proliferation, differentiation, […]
Read More →Science: Significant progress! Developed a new type of inflammatory inhibitor-small molecule OGG1 inhibitor
Inflammation Inflammation is a self-limiting, localized response to any tissue injury or trauma caused by wounding or infection, and is characterized by redness, heat, pain and swelling (rubor, calor, dolor, […]
Read More →JAK Inhibitors for Rheumatoid Arthritis
Biologics have changed the landscape of therapy for rheumatoid arthritis (RA). While they have substantially improved outcomes in patients with RA who are disease-modifying antirheumatic drug (DMARD) incomplete responders (IRs), they require administration via […]
Read More →